Table 2 Demographic and clinical characteristics of patients who had a diagnosis of laboratory-confirmed RR-TB reported to the COJ for tracing between July 2011–June 2012 (n = 594) and July 2013–June 2014 (n = 713) and those included in the treatment outcomes sub-study (n = 537)

Gender

n, %

 Male

307 (51.6)

397 (55.6)

279 (51.9)

 Female

287 (48.3)

316 (44.3)

258 (48.0)

Age, years

Median, IQR

34 (29–42)

37 (30–44)

36 (29–43)

  < 30

162 (27.3)

161 (22.6)

138 (25.7)

 30–45

308 (51.9)

376 (52.7)

282 (52.5)

 45–60

105 (17.6)

159 (22.3)

106 (19.7)

  ≥ 60

19 (3.2)

17 (2.4)

11 (2.1)

DR-TB classification

n, %

 RR-TB by Xpert MTB/RIF

158 (26.6)

316 (44.3)

237 (44.1)

 RIF mono-resistant TB

102 (17.2)

130 (18.2)

109 (20.3)

 MDR-TB

320 (53.8)

262 (36.8)

191 (35.6)

 XDR-TB

14 (2.4)

5 (0.7)

n/a

Sputum collection to diagnosis, days

Median, IQR

26 (7–36)

2 (1–7)

13 (7–28)

Diagnosis method from the COJ register

n, %

 Xpert MTB/RIF

258 (43.4)

431 (60.5)

337 (62.8)

 Geno Type MTBDR plus line probe assay

281 (47.3)

242 (33.9)

172 (32.0)

 Phenotypic drug sensitivity testing

30 (5.1)

2 (0.3)

6 (1.1)

 Unknown

25 (4.2)

38 (5.3)

22 (4.1)

AFB smear microscopy

n, %

 Positive

144 (24.3)

119 (16.7)

94 (17.4)

 Negative

78 (13.1)

49 (6.9)

44 (8.2)

 Unknown

372 (62.6)

545 (76.4)

400 (74.4)

HIV status at initiation

n, %

 Positive

155 (26.1)

336 (47.1)

428 (79.7)

  HIV positive on ART

n/a

n/a

351/428 (82.0)

  HIV positive not on ART

n/a

n/a

77/428 (17.9)

 HIV Negative

24 (4.0)

78 (10.9)

61 (11.4)

 Unknown

415 (69.9)

299 (42.0)

48 (8.9)

Time on ART, months

Median, IQR

 ART initiation before TB treatment initiation (n = 171)

n/a

n/a

9.6 (3.1–27.4)

 ART initiation after TB treatment initiation (n = 117)

n/a

n/a

0.5 (0.4–0.9)